This phase 2 study looked at the use of stereotactic radiotherapy to treat metastatic renal cell carcinoma (RCC) in patients where the cancer had spread and there were a small number of metastases. These patients were on a tyrosine kinase inhibitor as the first or second medicine for their cancer. The aim of the study […]
Stereotactic radiotherapy is a very precise method of radiotherapy that uses fewer doses of radiation than conventional radiotherapy. In this study of 37 patients with spread of their cancer (metastases) at a limited number of places in the body, the researchers looked at how stereotactic radiotherapy affected the outcomes of patients on tyrosine kinase inhibitors, […]
The US Food and Drug Administration (FDA) has approved the combination of pembrolizumab, an anti-PD-1 immunotherapy, plus lenvatinib, an oral tyrosine kinase inhibitor, for the first-line treatment of people with advanced renal cell carcinoma (RCC). The approval is based on the results from the phase 3 CLEAR/KEYNOTE-581 trial, in which the combination showed significant improvement […]
This study looked at the safety and effectiveness of targeted therapies or immune checkpoint inhibitors (immunotherapy) in combination with stereotactic radiotherapy in patients with renal cell carcinoma (RCC). There were 53 patients in the study, of whom 32% were treated with immunotherapy and 68% targeted therapy. About a third of patients on targeted therapy paused […]
Some very interesting work has been coming out of the Francis Crick Institute in London about the evolution of kidney tumours. The research is being led by Dr Samra Turajlic who also works at the Royal Marsden Hospital in London and is one of KCSN’s trustees. Here is her explanation of this very exciting work: […]
Research published in the journal Nature Ecology and Evolution led by scientists from the Francis Crick Institute, Royal Marsden, University College London and Cruces University Hospital has found that cells from different parts of kidney tumours behave differently. The researchers have discovered that cells from the centre of a kidney cancer tumour are the most […]
There is very little information on the effectiveness of sunitinib (a vascular endothelial growth factor (VEGF) inhibitor) as a second-line treatment after first-line treatment with immunotherapy for patients with metastatic renal cell carcinoma (RCC). A study published in Clinical Genitourinary Cancer last month looked at 102 patients in a real-world setting who were treated with […]
A recent study published in JAMA Network Open looked at the data from over 10,000 renal cell carcinoma (RCC) patients from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and reported on the sites of metastases for three of the RCC subtypes and their survival outcomes. Metastases from clear cell RCC (9252 patients, 92%) […]
A recent study published in the International Journal of Clinical Oncology looked at the distribution of metastases in patients with metastatic renal cell carcinoma (RCC) according to age and sex. 9,607 patients with metastatic RCC were identified from the National Inpatient Sample database (2008-2015) and analysed for site of metastases according to age and sex. […]
In this study, the researchers looked at the interaction between obesity and outcomes in patients taking immune checkpoint inhibitors (anti-PD-1 immunotherapy, e.g. nivolumab, pembrolizumab) for the treatment of renal cell carcinoma (RCC). Seventy-two (72) patients with metastatic RCC were treated with anti–PD-1 immunotherapy (none had been treated with immunotherapy before). Obese patients had poorer progression-free […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
